PREVENTion of Clot in Orthopaedic Trauma
- Co-PI: Renan Castillo, PhD
- Funders: Major Extremity Trauma Research Consortium (METRC); Patient-Centered Outcomes Research Institute (PCORI)
- Status: Ongoing
Each year, 6 million fractures are treated in the United States, and 2.3 million patients are admitted to hospitals after sustaining a serious fracture. People who fracture certain bones, such as the hip or thighbone, have a high risk of getting blood clots. The purpose of this study is to investigate the effectiveness of Low Molecular Weight Heparin (LMWH) compared to Aspirin in preventing death and clinically important pulmonary blood clots in patients who sustain orthopaedic trauma.
The study includes 18 trauma hospitals across the United States and Canada. The research team is monitoring patients for three months after their fractures to see which group has fewer deaths because of a blood clot in their lungs and fewer complications such as blood clots in their legs, internal bleeding, or infections. In addition, the research team is comparing the two groups’ satisfaction and out-of-pocket costs.
Haac BE, O’Hara NN, Mullins CD, Stein DM, Manson TT, Johal H, Castillo R, O'Toole RV, Slobogean GP. Patient preferences for venous thromboembolism prophylaxis after injury: a discrete choice experiment. BMJ Open. 2017;7(8):e016676. doi:10.1136/bmjopen-2017-016676.
ClinicalTrials.gov Identifier: NCT02984384
Comparing Medicines that Prevent Blood Clots for Emergency Room Patients with Serious Fractures - The PREVENT CLOT Study